Por: RTTNews Health December 20, 2023
Indivior PLC (INDV,) announced that its subsidiaries Indivior Inc. and Indivior UK, entered into a settlement agreement with Actavis Laboratories UT, a unit of Teva Pharmaceuticals, to resolve patent disputes regarding Actavis's Abbreviated New Drug Application for generic buprenorphine and naloxone sublingual film. Indivior granted Actavis a license to U.S. Patent that would enable Actavis to launch the generic film products identified in... + full article
Politico USA Health August 22, 2023
Two generic drug giants agreed Monday to settle long-running criminal price-fixing charges with the Justice Department, including the unusual move to sell off the drugs involved. The U.S. arms of and are paying $225 million and $30 million, respectively, according to court... + más
Antitrust Has a Generic-Drug Problem | The Atlantic
How one U.S. drugmaker contributed to the escalating drug shortage crisis | NBC News
MarketWatch USA Business May 18, 2023
Teva’s ADR jumped 7.3% on Thursday morning, as investors awaited an investor day presentation scheduled to start at 12 p.m. Eastern. The drugmaker has been struggling since a series of ill-advised acquisitions a decade ago, notably the decision to buy Actavis Generics for... + más
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis | ABC News
What Are the Duties of A Trustee? | Forbes
WPLG Local 10 USA Health November 03, 2022
NEW YORK – New York will receive up to $524 million from drugmaker Teva to settle claims that the company contributed to the U.S. opioid epidemic, the largest amount secured from an opioid manufacturer or distributor sued by the state, Attorney General Letitia James announced... + más
New York could get $524M under opioid settlements with Teva | ABC News
ABC News USA Health November 03, 2022
Teva Pharmaceuticals agreed Thursday to pay $523 million to settle claims stemming from the company’s role in the It’s the largest settlement New York has reached with an individual opioid defendant and raises the total amount secured from opioid manufacturers and... + más
New York Attorney General Letitia James secures $523 million from Teva Pharmaceuticals for role in opioid crisis | CNN
Teva Pharmaceuticals Will Pay Up To $523 Million In New York For Opioid Settlement | Forbes
NEW YORK -- New York will receive up to $524 million from drugmaker Teva to settle claims that the company contributed to the U.S. opioid epidemic, the largest amount secured from an opioid manufacturer or distributor sued by the state, Attorney General Letitia James announced... + más
New York could get $524M under opioid settlements with Teva | WPLG Local 10
Time USA Health October 14, 2022
Teva Pharmaceutical Industries Ltd.’s shortage of Adderall is expected to last through March, longer than the two to three months the company , according to U.S. regulators. The popular treatment for attention-deficit/hyperactivity disorder has been in short supply since at... + más
Did COVID-19 pandemic contribute to Adderall shortage? | ABC News
Did COVID-19 pandemic contribute to Adderall shortage? | ABC7
Los Angeles Times USA Opinion September 24, 2022
Carvedilol could be the poster child for how to lower drug prices. Since 2007, over 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which cost 2 cents a dose compared with $4.81 for the brand-name product. Patents on... + más
Here's what Medicare recipients should know about Inflation Reduction Act | 10 WBNS
FDA warns against 'very unsafe' social media trends targeted at teenagers | ABC News
About iurex | Privacy Policy | Disclaimer |